<p>Enliven Therapeutics（納斯達克代碼：ELVN - 獲取免費報告）預計將在 2026 年 5 月 13 日星期三市場開盤前發佈其 2026 年第一季度財報。分析師預計 Enliven Therapeutics 本季度每股收益為（$0.44）。感興趣的人員可以查看公司即將發佈的 2026 年第一季度財報的信息，瞭解定於 2026 年 5 月 11 日星期一東部時間下午 4:00 的電話會議的最新細節。</p>
<p>獲取 <strong>Enliven Therapeutics</strong> 的提醒：</p>
<p>Enliven Therapeutics（納斯達克代碼：ELVN - 獲取免費報告）最近一次公佈財報是在 3 月 3 日星期二。公司報告本季度每股收益為（$0.48），低於分析師一致預期的（$0.42），差距為（$0.06）。分析師平均預計 Enliven Therapeutics 在當前財年每股收益為-$2，在下一個財年每股收益也為-$2。</p>
<h2>Enliven Therapeutics 股票下跌 0.1%</h2>
<p>ELVN 的股票在星期三開盤時為$41.58。該公司的市值為 25.3 億美元，市盈率為-22.35，貝塔值為 0.32。該公司的 50 日移動平均為$36.54，200 日移動平均為$27.06。Enliven Therapeutics 的 12 個月低點為$14.78，12 個月高點為$48.53。</p>
<h2>分析師評級變動</h2>
<p>幾位股票研究分析師最近對該股票發表了看法。HC Wainwright 在 3 月 26 日星期四的研究報告中將 Enliven Therapeutics 的目標股價從$48.00 上調至$56.00，並給予該公司 “買入” 評級。Wall Street Zen 在週日的研究報告中將 Enliven Therapeutics 的股票評級從 “持有” 下調至 “賣出”。Weiss Ratings 在 4 月 20 日星期一的研究報告中重新發布了對 Enliven Therapeutics 的 “賣出（d-）” 評級。最後，瑞穗證券在 3 月 25 日星期三的研究報告中將 Enliven Therapeutics 的目標股價從$41.00 上調至$45.00，並給予該公司 “跑贏大盤” 評級。五位分析師對該股票給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “適度買入”，平均目標價格為$43.40。</p>
<p><strong>查看我們關於 Enliven Therapeutics 的最新報告</strong></p>
<h2>內部人員買賣</h2>
<p>在相關消息中，董事 Richard A. Heyman 在 2 月 17 日星期二出售了 1,230 股公司的股票。該股票以平均價格$26.18 出售，總價值為$32,201.40。出售後，該董事在公司持有 22,647 股，價值約為$592,898.46。這筆交易代表其持股比例下降了 5.15%。該出售在提交給 SEC 的文件中披露，相關文件可通過 SEC 網站訪問。此外，首席財務官 Benjamin Hohl 在 3 月 6 日星期五出售了 10,000 股公司的股票。該股票以平均價格$29.58 出售，總交易額為$295,800.00。出售完成後，首席財務官在公司持有 51,000 股，價值為$1,508,580。這代表其持股比例下降了 16.39%。該出售的 SEC 文件提供了更多信息。在上個季度，內部人員出售了價值$473,201 的 16,230 股公司股票。內部人員持有 25.90% 的股票。</p>
<h2>機構投資者對 Enliven Therapeutics 的看法</h2>
<p>幾家機構投資者和對沖基金最近增加或減少了對該股票的持股。Commodore Capital LP 在第二季度將其在 Enliven Therapeutics 的持股增加了 0.4%。Commodore Capital LP 現在擁有 4,692,809 股公司股票，價值$94,138,000，在上個季度購買了額外的 17,809 股。Vestal Point Capital LP 在第四季度將其在 Enliven Therapeutics 的持股增加了 230.2%。Vestal Point Capital LP 現在擁有 3,830,000 股公司股票，價值$58,982,000，在上個季度額外收購了 2,670,000 股。Polar Capital Holdings Plc 在第三季度將其在 Enliven Therapeutics 的持股增加了 1.5%。Polar Capital Holdings Plc 現在擁有 3,095,007 股公司股票，價值$63,355,000，在上個季度額外收購了 44,713 股。先鋒集團在第三季度將其在 Enliven Therapeutics 的持股增加了 5.9%。先鋒集團現在擁有 2,553,014 股公司股票，價值$52,260,000，在上個季度額外收購了 142,378 股。最後，State Street Corp 在第四季度將其在 Enliven Therapeutics 的持股增加了 9.1%。State Street Corp 現在擁有 1,052,862 股公司股票，價值$16,214,000，在上個季度額外收購了 87,725 股。對沖基金和其他機構投資者持有公司 95.08% 的股票。</p>
<h2>Enliven Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Enliven Therapeutics 是一家臨牀階段的生物技術公司，專注於開發小分子療法，利用誘導接近機制選擇性地靶向和降解癌症中致病蛋白。該公司利用其專有的誘導接近平台，設計分子膠和相關方式，以招募內源性細胞機制進行靶向蛋白降解，目標是治療由所謂 “難以藥物化” 的腫瘤因子驅動的惡性腫瘤。</p>
<p>該公司的管道包括多個早期階段的項目，針對血液和實體腫瘤指示中的關鍵腫瘤驅動因子。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Enliven Therapeutics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUVMVk4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUVMVk4"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Enliven Therapeutics 嗎？</h2>
<p>在考慮 Enliven Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Enliven Therapeutics 並不在名單上。</p>
<p>雖然 Enliven Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ELVN

<p>Enliven Therapeutics（納斯達克代碼：ELVN）將於 5 月 13 日發佈 2026 年第一季度財報，分析師預測每股虧損為 0.44 美元。該公司最近報告了上一季度每股虧損 0.48 美元，未能達到預期。當前股價為 41.58 美元，市值為 25.3 億美元。分析師評級各異，五位分析師給予 “買入” 評級，一位給予 “賣出” 評級。內部交易活動包括首席財務官和一位董事的近期出售。機構投資者也已調整了在該公司的持股</p>

<p>Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) is anticipated to release its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Enliven Therapeutics to post earnings of ($0.44) per share for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.</p>
<div class="lb-trans"><p>Enliven Therapeutics（納斯達克代碼：ELVN - 獲取免費報告）預計將在 2026 年 5 月 13 日星期三市場開盤前發佈其 2026 年第一季度財報。分析師預計 Enliven Therapeutics 本季度每股收益為（$0.44）。感興趣的人員可以查看公司即將發佈的 2026 年第一季度財報的信息，瞭解定於 2026 年 5 月 11 日星期一東部時間下午 4:00 的電話會議的最新細節。</p>
</div><p>Get <strong>Enliven Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Enliven Therapeutics</strong> 的提醒：</p>
</div><p>Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.06). On average, analysts expect Enliven Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Enliven Therapeutics（納斯達克代碼：ELVN - 獲取免費報告）最近一次公佈財報是在 3 月 3 日星期二。公司報告本季度每股收益為（$0.48），低於分析師一致預期的（$0.42），差距為（$0.06）。分析師平均預計 Enliven Therapeutics 在當前財年每股收益為-$2，在下一個財年每股收益也為-$2。</p>
</div><h2>Enliven Therapeutics Stock Down 0.1%</h2>
<div class="lb-trans"><h2>Enliven Therapeutics 股票下跌 0.1%</h2>
</div><p>Shares of ELVN opened at $41.58 on Wednesday. The company has a market capitalization of $2.53 billion, a P/E ratio of -22.35 and a beta of 0.32. The firm has a 50 day moving average of $36.54 and a 200 day moving average of $27.06. Enliven Therapeutics has a twelve month low of $14.78 and a twelve month high of $48.53.</p>
<div class="lb-trans"><p>ELVN 的股票在星期三開盤時為$41.58。該公司的市值為 25.3 億美元，市盈率為-22.35，貝塔值為 0.32。該公司的 50 日移動平均為$36.54，200 日移動平均為$27.06。Enliven Therapeutics 的 12 個月低點為$14.78，12 個月高點為$48.53。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Several equities research analysts recently weighed in on the stock. HC Wainwright raised their price target on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, March 26th. Wall Street Zen downgraded shares of Enliven Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Sunday. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. Finally, Mizuho raised their price target on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the company an &#34;outperform&#34; rating in a research report on Wednesday, March 25th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $43.40.</p>
<div class="lb-trans"><p>幾位股票研究分析師最近對該股票發表了看法。HC Wainwright 在 3 月 26 日星期四的研究報告中將 Enliven Therapeutics 的目標股價從$48.00 上調至$56.00，並給予該公司 “買入” 評級。Wall Street Zen 在週日的研究報告中將 Enliven Therapeutics 的股票評級從 “持有” 下調至 “賣出”。Weiss Ratings 在 4 月 20 日星期一的研究報告中重新發布了對 Enliven Therapeutics 的 “賣出（d-）” 評級。最後，瑞穗證券在 3 月 25 日星期三的研究報告中將 Enliven Therapeutics 的目標股價從$41.00 上調至$45.00，並給予該公司 “跑贏大盤” 評級。五位分析師對該股票給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “適度買入”，平均目標價格為$43.40。</p>
</div><p><strong>View Our Latest Report on Enliven Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Enliven Therapeutics 的最新報告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人員買賣</h2>
</div><p>In related news, Director Richard A. Heyman sold 1,230 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total value of $32,201.40. Following the sale, the director owned 22,647 shares in the company, valued at approximately $592,898.46. This trade represents a 5.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Benjamin Hohl sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $29.58, for a total transaction of $295,800.00. Following the completion of the sale, the chief financial officer owned 51,000 shares in the company, valued at $1,508,580. This represents a 16.39% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 16,230 shares of company stock worth $473,201. 25.90% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事 Richard A. Heyman 在 2 月 17 日星期二出售了 1,230 股公司的股票。該股票以平均價格$26.18 出售，總價值為$32,201.40。出售後，該董事在公司持有 22,647 股，價值約為$592,898.46。這筆交易代表其持股比例下降了 5.15%。該出售在提交給 SEC 的文件中披露，相關文件可通過 SEC 網站訪問。此外，首席財務官 Benjamin Hohl 在 3 月 6 日星期五出售了 10,000 股公司的股票。該股票以平均價格$29.58 出售，總交易額為$295,800.00。出售完成後，首席財務官在公司持有 51,000 股，價值為$1,508,580。這代表其持股比例下降了 16.39%。該出售的 SEC 文件提供了更多信息。在上個季度，內部人員出售了價值$473,201 的 16,230 股公司股票。內部人員持有 25.90% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Enliven Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Enliven Therapeutics 的看法</h2>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Commodore Capital LP boosted its holdings in Enliven Therapeutics by 0.4% in the second quarter. Commodore Capital LP now owns 4,692,809 shares of the company's stock worth $94,138,000 after purchasing an additional 17,809 shares during the last quarter. Vestal Point Capital LP boosted its stake in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company's stock worth $58,982,000 after acquiring an additional 2,670,000 shares during the last quarter. Polar Capital Holdings Plc boosted its stake in shares of Enliven Therapeutics by 1.5% during the 3rd quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company's stock worth $63,355,000 after acquiring an additional 44,713 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Enliven Therapeutics by 5.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company's stock worth $52,260,000 after acquiring an additional 142,378 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Enliven Therapeutics by 9.1% during the 4th quarter. State Street Corp now owns 1,052,862 shares of the company's stock worth $16,214,000 after acquiring an additional 87,725 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近增加或減少了對該股票的持股。Commodore Capital LP 在第二季度將其在 Enliven Therapeutics 的持股增加了 0.4%。Commodore Capital LP 現在擁有 4,692,809 股公司股票，價值$94,138,000，在上個季度購買了額外的 17,809 股。Vestal Point Capital LP 在第四季度將其在 Enliven Therapeutics 的持股增加了 230.2%。Vestal Point Capital LP 現在擁有 3,830,000 股公司股票，價值$58,982,000，在上個季度額外收購了 2,670,000 股。Polar Capital Holdings Plc 在第三季度將其在 Enliven Therapeutics 的持股增加了 1.5%。Polar Capital Holdings Plc 現在擁有 3,095,007 股公司股票，價值$63,355,000，在上個季度額外收購了 44,713 股。先鋒集團在第三季度將其在 Enliven Therapeutics 的持股增加了 5.9%。先鋒集團現在擁有 2,553,014 股公司股票，價值$52,260,000，在上個季度額外收購了 142,378 股。最後，State Street Corp 在第四季度將其在 Enliven Therapeutics 的持股增加了 9.1%。State Street Corp 現在擁有 1,052,862 股公司股票，價值$16,214,000，在上個季度額外收購了 87,725 股。對沖基金和其他機構投資者持有公司 95.08% 的股票。</p>
</div><h2>Enliven Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Enliven Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.</p>
<div class="lb-trans"><p>Enliven Therapeutics 是一家臨牀階段的生物技術公司，專注於開發小分子療法，利用誘導接近機制選擇性地靶向和降解癌症中致病蛋白。該公司利用其專有的誘導接近平台，設計分子膠和相關方式，以招募內源性細胞機制進行靶向蛋白降解，目標是治療由所謂 “難以藥物化” 的腫瘤因子驅動的惡性腫瘤。</p>
</div><p>The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.</p>
<div class="lb-trans"><p>該公司的管道包括多個早期階段的項目，針對血液和實體腫瘤指示中的關鍵腫瘤驅動因子。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Enliven Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Enliven Therapeutics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RUxWTg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=ELVN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Enliven Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Enliven Therapeutics 嗎？</h2>
</div><p>Before you consider Enliven Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Enliven Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Enliven Therapeutics 並不在名單上。</p>
</div><p>While Enliven Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Enliven Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Enliven Therapeutics (ELVN) 預計將在週三發佈財報